Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12986690 | 0.78 | L3MBTL1 (0.50) | L3MBTL1HDAC6 | |
| SCHEMBL12986658 | 0.78 | L3MBTL1 (0.49) | L3MBTL1HTR2CHTR2AHDAC6 | |
| SCHEMBL12986160 | 0.77 | TTK (0.41) | TTK | |
| SCHEMBL457296 | 0.76 | TRPM5 (0.32) | TTK | |
| SCHEMBL13192519 | 0.74 | TTK (0.33) | TTK | |
| SCHEMBL7354198 | 0.73 | L3MBTL1 (0.62) | L3MBTL1HTR2CHTR2AHDAC6 | |
| SCHEMBL14382231 | 0.73 | L3MBTL1 (0.57) | L3MBTL1HTR2CHTR2AHDAC6 | |
| SCHEMBL14006673 | 0.73 | L3MBTL1 (0.47) | L3MBTL1 | |
| SCHEMBL13526947 | 0.73 | L3MBTL1 (0.57) | L3MBTL1HTR2CHTR2A | |
| SCHEMBL13193052 | 0.72 | TTK (0.46) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694500-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma AG (DE) | 2015-05-27 | — | — | EP | disclosed |
| EP-2694500-B1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma AG (DE) | 2015-05-27 | — | — | EP | disclosed |
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-11 | — | — | US | disclosed |
| EP-2694500-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012136531-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255392-A1 | SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF | FLT4, KDR, VEGFA | L3MBTL1 2809/4885HTR2C 2376/4885HTR2A 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.